Non-Small Cell Lung Cancer
Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)
Anika Sharma
ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...
Merck’s Keytruda extends survival of early lung cancer patients in trial, awaits FDA approval
Anika Sharma
Merck & Co.’s Keytruda has achieved a groundbreaking milestone in the treatment landscape for early-stage non-small cell lung cancer (NSCLC), ...
Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio
Anika Sharma
Mirati Therapeutics, long speculated to be a potential acquisition target in the world of Big Pharma, has now sealed a ...
Keytruda-Lenvima combo fails to improve survival in two lung cancer trials
Anika Sharma
Merck and Eisai’s collaborative effort with Keytruda and Lenvima faces yet another setback in their quest to combat cancer. Despite ...
Enhertu, a Breakthrough Therapy for HER2 Mutant NSCLC, Gets EU Nod
Anika Sharma
Enhertu (trastuzumab deruxtecan) has received a positive recommendation for approval in the European Union (EU) as a standalone treatment for ...
